BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 16, 2012
View Archived Issues
Novel small molecules target RNA binding site of human DDX3X
Read More
Telaprevir improves hepatitis C therapy in HIV-1-coinfected patients
Read More
Anti-fibrillogenic agents designed via out-of-plane substitutions show therapeutic potential
Read More
Studies demonstrate various therapeutic applications for SEH inhibition
Read More
Horizon Discovery and RFUMS to develop human cellular CF model
Read More
Recruitment complete in phase II BVT-115959 trial
Read More
Mologen seeks approval for study of MGN-1703 in NSCLC
Read More
OncoSec begins enrollment at two new sites for metastatic melanoma trial
Read More
New P2X4 receptor antagonist is active in models of neuropathic pain
Read More
Marina Biotech and ProNAi Therapeutics enter license agreement for DNAi-based therapies
Read More
New dipeptide calpain inhibitors reported by Banyan Biomarkers
Read More
Enanta presents novel candidate hepatitis C drugs
Read More
Novel p53-based peptidomimetics developed at Aileron Therapeutics
Read More
Shionogi & Co. divulges novel potential obesity drugs
Read More
Novel anti-infectives announced by Novacta Biosystems
Read More
Almirall attains new marketing rights to Sativex
Read More
Abbott begins phase III studies in hidradenitis suppurativa
Read More
Biogen Idec and MAKScientific enter MS agreement
Read More
Shire announces planned acquisition
Read More
Grifols acquires majority share in Araclon Biotech
Read More
Treatment begins in phase III study of CSL Behring's fibrinogen concentrate
Read More
Clinuvel provides update on phase III Scenesse trial
Read More
Aeras receives grant to develop new vaccines against TB
Read More
Thrombogenics and Alcon enter commercialization agreement for ocriplasmin
Read More
Novartis withdraws applications for new rivastigmine indication
Read More
Repligen commences first-in-human trial of HD inhibitor in Friedreich's ataxia
Read More
